Preferencje help
Polish version English version Język
Widoczny [Schowaj] Abstrakt
Liczba wyników

Znaleziono wyników: 15

Liczba wyników na stronie
Pierwsza strona wyników Pięć stron wyników wstecz Poprzednia strona wyników Strona / 1 Następna strona wyników Pięć stron wyników wprzód Ostatnia strona wyników

Wyniki wyszukiwania

help Sortuj według:

help Ogranicz wyniki do:
Pierwsza strona wyników Pięć stron wyników wstecz Poprzednia strona wyników Strona / 1 Następna strona wyników Pięć stron wyników wprzód Ostatnia strona wyników
1

Immunostymulacyjne wlasciwosci sekwencji CpG w bakteryjnym DNA

100%
Smolarczyk R., Szala S.
Postępy Biochemii
|
2004
|
tom 50
|
nr 4
296-303
2
Content available remote

Correlation between Helicobacter pylori infection and pulmonary Wegener's granulomatosis activity

81%
Zycinska K., Wardyn K. A., Zycinski Z., Smolarczyk R.
Journal of Physiology and Pharmacology. Supplement
|
2008
|
tom 59
|
nr 6
845-851
3

Combination of anticancer peptide (CAMEL) with immunotherapy in B16(F10) murine melanoma tumor therapy

71%
Smolarczyk R., Cichon T., Kamysz W., Nadolny R., Szala S.
Acta Biochimica Polonica
|
2007
|
tom 54
|
nr Supplement 4
4

Combined anticancer therapy using antivascular peptide and folate-targeted liposomes carrying doxorubicin

71%
Sochanik A. S., Smolarczyk R., Mitrus I., Cichon T., Szala S.
Acta Biochimica Polonica
|
2007
|
tom 54
|
nr Supplement 4
5

D-K6L9 peptide combination with IL-12 inhibits the recurrence of tumors in mice

61%
Cichon T., Smolarczyk R., Matuszczak S., Barczyk M., Jarosz M., Szala S.
Archivum Immunologiae et Therapiae Experimentalis
|
2014
|
tom 62
|
nr 4
6
Artykuł dostępny w postaci pełnego tekstu - kliknij by otworzyć plik
Content available

Takayasu’s arteritis: a rare disease in Poland

61%
Kanecki K., Nitsch-Osuch A., Tyszko P. Z., Gorynski P., Smolarczyk R., Suchta K.
Annals of Agricultural and Environmental Medicine
|
2018
|
tom 25
|
nr 3
7

Combined tumor cell-based vaccination and interleukin-12 gene therapy polarizes the tumor microenvironment in mice

61%
Jarosz-Biej M., Smolarczyk R., Cichon T., Kulach N., Czapla J., Matuszczak S., Szala S.
Archivum Immunologiae et Therapiae Experimentalis
|
2015
|
tom 63
|
nr 6
8
Artykuł dostępny w postaci pełnego tekstu - kliknij by otworzyć plik
Content available

Peroxiredoxin-1 as a prognostic factor in patients with ovarian cancer

61%
Sienko J., Teliga-Czajkowska J., Przytula E., Czajkowski K., Smolarczyk R., Nowis D.
Annals of Agricultural and Environmental Medicine
|
2019
|
tom 26
|
nr 3
9

Experimental anticancer therapy with vascular-disruptive peptide and liposome-entrapped chemotherapeutic agent

61%
Sochanik A., Mitrus I., Smolarczyk R., Cichon T., Snietura M., Czaja M., Szala S.
Archivum Immunologiae et Therapiae Experimentalis
|
2010
|
tom 58
|
nr 3
235-245
10

Antitumor effect of RGD-4C-CG-D(KLAKLAK)2 peptide in mouse B16(F10) melanoma model

61%
Smolarczyk R., Cichon T., Graja K., Hucz J., Sochanik A., Szala S.
Acta Biochimica Polonica
|
2006
|
tom 53
|
nr 4
11

In vivo gene transfer using cetylated polyethylenimine

61%
Sochanik A., Cichon T., Makselon M., Strozyk M., Smolarczyk R., Jazowiecka-Rakus J., Szala S.
Acta Biochimica Polonica
|
2004
|
tom 51
|
nr 3
This report describes gene transfer in vitro as well as in vivo using cetylated low-molecular mass (600 Da) polyethylenimine (28% of amine groups substituted with cetyl moieties), termed CT-PEI. This compound is hydrophobic and has to be in­corporated into liposomes in order to be suitable for gene transfer studies. Serum-in­duced plasmid DNA degradation assay demonstrated that CT-PEI-containing lipo­somal carriers could protect complexed DNA (probably via condensation). In vitro lu- ciferase gene expression achieved using medium supplemented with 10% serum was comparable to that achieved in serum-reduced medium and was highest for CT-PEI/cholesterol liposomes, followed by CT-PEI/dioleoylphosphatidylcholine liposomes and PEI 600 Da (uncetylated) carrier. In vivo systemic transfer into mice was most efficient when liposome formulations contained CT-PEI and cholesterol. Higher luciferase expression was then observed in lungs than in liver. In conclusion: liposomes containing cetylated polyethylenimine and cholesterol are a suitable vehicle for investigating systemic plasmid DNA transfer into lungs.
12

Vasostatin increases oxygenation of B16-F10 melanoma tumors and raises therapeutic efficacy of cyclophosphamide

51%
Cichon T., Jarosz M., Smolarczyk R., Ogorek B., Matuszczak S., Wagner M., Mitrus I., Sochanik A., Jazowiecka-Rakus J., Szala S.
Acta Biochimica Polonica
|
2012
|
tom 59
|
nr 3
One of the preconditions of effective anticancer therapy is efficient transfer of the therapeutic agent (chemotherapeutic) to tumor cells. Fundamental barriers making drug delivery and action difficult include underoxygenation, elevated interstitial pressure, poor and abnormal tumor blood vascular network and acidic tumor milieu. In this study we aimed at developing an optimized scheme of administering a combination of an angiogenesis-inhibiting drug (vasostatin) and a chemotherapeutic (cyclophosphamide) in the therapeutic treatment of mice bearing experimental B16-F10 melanoma tumors. We report that the strongest tumor growth inhibition was observed in mice that received two, three or four vasostatin doses in combination with one injection of cyclophosphamide (i.e., V2 + CTX, V3 + CTX or V4 + CTX schemes). Double administration of vasostatin increases oxygenation of B16-F10 tumors. On the other hand, its five-fold administration lowers tumor oxygenation, breaks down tumor vascular network (increasing hypoxia) and leads in consequence to death of cancer cells and appearance of necrotic areas in the tumor. A decreased cyclophosphamide dose in combination with two doses of vasostatin (V2 + CTX scheme) inhibits tumor growth similarly to a larger dose of cyclophosphamide alone.
13

The role of glycyrrhizin, an inhibitor of HMGB1 protein, in anticancer therapy

51%
Smolarczyk R., Cichon T., Matuszczak S., Mitrus I., Lesiak M., Kobusinska M., Kamysz W., Jarosz M., Sieron A., Szala S.
Archivum Immunologiae et Therapiae Experimentalis
|
2012
|
tom 60
|
nr 5
14

Antitumor effects of recombinant antivascular protein ABRaA-VEGF121 combined with IL-12 gene therapy

51%
Ciomber A., Smagur A., Mitrus I., Cichon T., Smolarczyk R., Sochanik A., Szala S., Jarosz M.
Archivum Immunologiae et Therapiae Experimentalis
|
2014
|
tom 62
|
nr 2
15

Overexpression of heme oxygenase in murine melanoma: increased proliferation and viability of tumor cells, decreased survival of mice

42%
Was H., Ciechon T., Smolarczyk R., Rudnnicka D., Chevalier C., Leger J. J., Lackowksa B., Grochot A., Bojkowska K., Ratajska A., Kieda C., Szala S., Dulak J., Jozkowicz A.
Acta Biochimica Polonica
|
2006
|
tom 53
|
nr Supplement 1
Pierwsza strona wyników Pięć stron wyników wstecz Poprzednia strona wyników Strona / 1 Następna strona wyników Pięć stron wyników wprzód Ostatnia strona wyników
JavaScript jest wyłączony w Twojej przeglądarce internetowej. Włącz go, a następnie odśwież stronę, aby móc w pełni z niej korzystać.